Analysts do not expect odanacatib to be a major earner.
The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."
Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.
The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.
The drug did not hit its Phase III primary target of improving progression-free survival.
Novartis and the nonprofit Banner Alzheimer's Institutes are testing a theory that treating healthy patients could prevent or delay Alzheimer's disease.
Allergan's latest pipeline news was a mix of the good and the bad. The good: a potential Lucentis competitor is progressing. The bad: migraine medication Semprana has stalled.
The regulator wants men to be part of breast cancer clinical trials.
Phase III results showing improved lung function among cystic fibrosis patients using a combination of Kalydeco and lumacaftor means drugmaker Vertex is filing the two-part drug for FDA approval during the fourth quarter.
GlaxoSmithKline dismissed a marketer over its approach to clinical trial recruiting.
Researchers are increasingly using social media to recruit patients, albeit oftentimes in an arms-length manner.
Researchers find worries about being misunderstood or mixed in with "junk" news are among the reasons academic researchers are keeping their data points out of the social media swirl. Researchers say this fear is at the expense of a faster way to make an impact on public policy.
The regulator is allocating almost $38 million to improve data-guided decision-making.
The companies announced Tuesday that Arzerra, already indicated for leukemia, failed to outdo Roche's Rituxan in the lymphoma setting.
The Securities and Exchange Commission alleges that two doctors illegally exploited their clinical trial affiliation for financial gain.
Both companies revealed Phase-III data for idiopathic pulmonary fibrosis treatments. The progressive disease generally kills patients within three years of diagnosis.
The National Institutes of Health wants female lab animals to be part of the animal testing mix.
The drugmaker announced Wednesday that researchers would be able to access clinical trial data.
GlaxoSmithKline announced Tuesday its Phase-III drug from the Human Genome Sciences acquisition failed to hit its primary endpoint.
The company announced Monday that researchers will be able to seek out clinical trial data going back to 1998.
The company said it plans to file its rare-disease drug with the FDA later this year, for a 2015 review.
Roche also announced first-quarter sales shrank 1%.
Phase-II results indicate Merck's all-in-one HCV oral could put pressure on Gilead.
The FDA issued an official halt, five days after Halozyme stopped the Phase-II trial because of patient stroke information.
Analyses by Jefferies indicate that although doctors are interested in the experimental anti-cholesterol drugs, CV data will be a critical differentiator.
The drugmaker halted Phase III trials of a three-month medication based on good efficacy feedback.
The company says it will continue to test its MAGE-A3 cancer drug among a subset of non-small cell lung cancer patients and among melanoma patients.
A working group set out parameters for what counts as a meaningful outcome for pancreatic, breast, lung and colon cancer clinical trials.
PhRMA and the National Minority Quality Forum's "I'm In" campaign seeks to tackle clinical trial diversity (or the lack thereof).
Pfizer hit its endpoints for preventing pneumonia among the elderly, but the data may not be robust enough to spur vaccination.
*Group discounts available on request
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.